STOCKHOLM, Sweden, Feb. 21, 2005 (PRIMEZONE) -- Biolipox:
Full-year 2004
-- Biolipox secure additional funding -- international venture
capital firms invest EUR 30 million
-- NLA Nasal Spray for the treatment of rhinitis shows good
efficacy in phase II study
-- Progress in projects leads to several patent applications
-- Early drug development organisation further expanded
-- Net sales amounted to SEK 0 (0)
-- Results after tax amounted to a loss of SEK 96.7 million
(loss: 63.3)
-- Earnings per share amounted to a loss of SEK 112.25 (loss: 72.46)
For the complete Year-end report 2004, please visit www.biolipox.com/finansiella_rapporter.asp
For further information, please contact: Torbjorn Bjerke, President & CEO, Tel: +46 70 66 19 90, e-mail: torbjorn.bjerke@biolipox.com Peter Hein, CFO, Tel: +46 8 545 28 153, Cellular phone: +46 733 70 73 43, e-mail: peter.hein@biolipox.com
For fact sheets, images and illustrations, please visit www.biolipox.com/press
Biolipox AB (publ) is a Swedish, research-intensive pharmaceutical company focusing on the development of new, effective drugs for the treatment of respiratory and other inflammatory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), rhinitis, pain and arthritis (inflammatory diseases of the joints). Biolipox's scientific platform is represented by research into the metabolism of arachidonic acid -- arachidonic acid is an endogenous substance that indirectly influences several inflammatory processes in the body.
This information was brought to you by Waymaker http://www.waymaker.net
The full report is available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=74040&fn=wkr0001.pdf